Science Explorer Back to mapMap

Most cited papers from Ohio Pediatric Research Association

What are the most cited papers from Ohio Pediatric Research Association?

The most cited paper from Ohio Pediatric Research Association is "Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women" (Jorma A. Paavonen et al., 2009), with 1,663 citations. Next come "Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial" (1,320) and "Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial" (708).

Showing 50 of 60 papers. Every paper with more than 47 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women Jorma A. Paavonen et al. · The Lancet Jul 2009 1,663
2 Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial Jorma A. Paavonen et al. · The Lancet Jun 2007 1,320
3 Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Matti Lehtinen et al. · The Lancet Oncology 9 Nov 2011 708
4 Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience Suzanne Marie Garland, Susanne K. Kjær, Nubia Muñóz et al. · Clinical Infectious Diseases ReviewOpen access 26 May 2016 501
5 Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women Stan L. Block, Terry M. Nolan, Carlos A. Sattler et al. · PEDIATRICS Nov 2006 486
6 Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine Robert B. Belshe, William C. Gruber, Paul M. Mendelman et al. · The Journal of Pediatrics Feb 2000 434
7 Correlates of Immune Protection Induced by Live, Attenuated, Cold‐Adapted, Trivalent, Intranasal Influenza Virus Vaccine Robert B. Belshe, William C. Gruber, Paul M. Mendelman et al. · The Journal of Infectious Diseases Mar 2000 414
8 Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia Stan Block, JAMES A. HEDRICK, Margaret R. Hammerschlag et al. · The Pediatric Infectious Disease Journal Jun 1995 344
9 Community-Wide Vaccination with the Heptavalent Pneumococcal Conjugate Significantly Alters the Microbiology of Acute Otitis Media Stan L. Block, JAMES A. HEDRICK, Christopher J Harrison et al. · The Pediatric Infectious Disease Journal Sep 2004 329
10 Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents Keith S. Reisinger, Stan L. Block, Eduardo Cesar Lazcano-Ponce et al. · The Pediatric Infectious Disease Journal 27 Feb 2007 298
11 Penicillin-resistant Streptococcus pneumoniae in acute otitis media Stan L. Block, Christopher J. Harrison, JAMES A. HEDRICK et al. · The Pediatric Infectious Disease Journal Sep 1995 260
12 Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial JAMES A. HEDRICK, Asher Barzilai, Ulrich Behre et al. · The Pediatric Infectious Disease Journal May 2000 246
13 Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers Sylvia H. Yeh, Alejandra Gurtman, David C. Hurley et al. · PEDIATRICS 24 Aug 2010 238
14 Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study Unnop Jaisamrarn et al. · PLoS ONE Open access 19 Nov 2013 218
15 Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women Ole‐Erik Iversen et al. · JAMA 28 Nov 2016 214
16 Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Kristina A. Bryant, Stan L. Block, Sherryl A. Baker et al. · PEDIATRICS 30 Apr 2010 188
17 High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community Jeffrey S. Duchin, Robert F. Breiman, Ann Stuart Diamond et al. · The Pediatric Infectious Disease Journal Sep 1995 165
18 Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media Stan L. Block · The Pediatric Infectious Disease Journal Apr 1997 155
19 Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children Alejandro Hoberman, Jack L. Paradise, Howard E. Rockette et al. · New England Journal of Medicine Open access 21 Dec 2016 146
20 Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18 Anne Szarewski et al. · International Journal of Cancer Open access 19 Aug 2011 143
21 Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial Judith Absalon, Nathan Segall, Stan L. Block et al. · The Lancet Infectious Diseases Open access 3 Sep 2020 139
22 Efficacy, Immunogenicity, and Safety of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine at the End of Shelf Life Stan L. Block, Timo Vesikari, Michelle G. Goveia et al. · PEDIATRICS 2007 138
23 Immunogenicity and Safety of a 9-Valent HPV Vaccine Pierre Van Damme, Sven Eric Olsson, S. Block et al. · PEDIATRICS Open access 23 Jun 2015 135
24 An Overview of Quadrivalent Human Papillomavirus Vaccine Safety Michelle D. Vichnin, Paolo Bonanni, Nicola P. Klein et al. · The Pediatric Infectious Disease Journal Open access 23 Jun 2015 127
25 Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children Jeffrey P. Baker, Stanley L. Block, Balpreet Matharu et al. · The Pediatric Infectious Disease Journal Open access 19 May 2020 124
26 Parents' decision-making regarding vaccinating their children against influenza: A web-based survey Emuella M. Flood, Matthew D. Rousculp, Kellie J. Ryan et al. · Clinical Therapeutics Aug 2010 123
27 Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials Edson Duarte Moreira et al. · PEDIATRICS Open access 15 Jul 2016 120
28 Differential control of ATGL-mediated lipid droplet degradation by CGI-58 and G0S2 Xin Lü, Xingyuan Yang, Jun Liu · Cell Cycle Open access 15 Jul 2010 117
29 Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Stan L. Block, Darron R. Brown, Archana Chatterjee et al. · The Pediatric Infectious Disease Journal 29 Jan 2010 116
30 Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5–49 years of age Stan L. Block, Ram Yogev, Frederick G. Hayden et al. · Vaccine 27 Jul 2008 108
31 Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial Suzanne Marie Garland et al. · International Journal of Cancer Open access 19 Aug 2016 105
32 Long-term Study of a Quadrivalent Human Papillomavirus Vaccine Daron Ferris, Rudiwilai Samakoses, Stan L. Block et al. · PEDIATRICS 19 Aug 2014 104
33 Association of Proinflammatory Cytokine Gene Polymorphisms With Susceptibility to Otitis Media Janak A. Patel, Sangeeta Nair, Krystal Revai et al. · PEDIATRICS Dec 2006 95
34 Increasing Bacterial Resistance in Pediatric Acute Conjunctivitis (1997–1998) Stan L. Block, JAMES A. HEDRICK, Ron Tyler et al. · Antimicrobial Agents and Chemotherapy Open access Jun 2000 94
35 Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1) Joel Schlessinger, Julie S. Shepard, Richard Gower et al. · American Journal of Clinical Dermatology Open access 24 Mar 2020 91
36 Tympanostomy Tubes or Medical Management for Recurrent Acute Otitis Media Alejandro Hoberman et al. · New England Journal of Medicine Open access 12 May 2021 90
37 Quadrivalent Meningococcal Vaccination of Adults: Phase III Comparison of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, Menactra Keith S. Reisinger, Roger P. Baxter, Stanley L. Block et al. · Clinical and Vaccine Immunology Open access 8 Oct 2009 87
38 4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years Daron G. Ferris, Rudiwilai Samakoses, Stanley L. Block et al. · PEDIATRICS 22 Nov 2017 76
39 Immunogenicity and Safety of a Quadrivalent Live Attenuated Influenza Vaccine in Children Stan L. Block, Judith Falloon, Jeffrey A. Hirschfield et al. · The Pediatric Infectious Disease Journal 30 Mar 2012 75
40 Acellular Pertussis Vaccine Booster Combined With Diphtheria and Tetanus Toxoids for Adolescents Michael E. Pichichero, Mark M. Blatter, William A. II Kennedy et al. · PEDIATRICS Apr 2006 73
41 The Efficacy of Live Attenuated Influenza Vaccine Against Influenza-associated Acute Otitis Media in Children Stan L. Block, Terho Heikkinen, Seth L Toback et al. · The Pediatric Infectious Disease Journal 8 Oct 2010 73
42 Subunit Influenza Vaccines Produced from Cell Culture or in Embryonated Chicken Eggs: Comparison of Safety, Reactogenicity, and Immunogenicity Keith S. Reisinger, Stanley L. Block, Allen Izu et al. · The Journal of Infectious Diseases 12 Aug 2009 71
43 Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 months James C. King, Manon M. J. Cox, Keith S. Reisinger et al. · Vaccine 28 Aug 2009 69
44 Chlamydia pneumoniae in acute otitis media Stan L. Block, Margaret R. Hammerschlag, JAMES A. HEDRICK et al. · The Pediatric Infectious Disease Journal Sep 1997 66
45 A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults Stan L. Block, Tingting Yi, Eric A. Sheldon et al. · Vaccine 12 Oct 2011 64
46 Efficacy of amoxicillin/clavulanate for acute otitis media: relation to Streptococcus pneumoniae susceptibility Alejandro Hoberman, Jack L. Paradise, Stan Block et al. · The Pediatric Infectious Disease Journal Oct 1996 63
47 Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up Sven-Eric Olsson, Jaime Alberto Restrepo, Julio Cesar Reina et al. · Papillomavirus Research Open access 10 Jul 2020 61
48 Safety, Tolerability, and Immunogenicity of Gardasil Given Concomitantly With Menactra and Adacel Keith S. Reisinger, Stan L. Block, Michelle D. Collins-Ogle et al. · PEDIATRICS 4 May 2010 61
49 Adhesin Expression in Matched Nasopharyngeal and Middle Ear Isolates of Nontypeable Haemophilus influenzae from Children with Acute Otitis Media Graham P. Krasan, David Cutter, Stan L. Block et al. · Infection and Immunity Open access 1999 58
50 A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial Stan L. Block, Leszek Szenborn, Wendy Daly et al. · Vaccine 22 Mar 2015 58

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.